Side Effects of Second-Generation Antipsychotics: The Experiences, Views and Monitoring Practices of Australian Child Psychiatrists

Walter, Garry; DeLaroche, Amy M.; Soh, Nerissa; Hunt, Glenn E.; Cleary, Michelle; Malhi, Gin S; Lambert, Tim; Correll, Christoph U.; Rey, Joseph M.

doi:10.1080/10398560801958549

Cited by 38 publications

(41 citation statements)

References 66 publications

(210 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Experts in health care improvement have emphasized the need to understand the problem, identify groups that should be targeted by efforts to improve adherence, and clarify barriers to implementation of adherence with guidelines. We identified three previous surveys of child psychiatrists that assessed monitoring of second-generation antipsychotics (3)(4)(5). In a U.S. survey of 334 child psychiatrists (published after the current survey was conducted), 53% of the respondents reported that patients were noncompliant with blood tests, but the study did not explore other barriers to monitoring (4).…”

mentioning

confidence: 96%

Monitoring of Patients on Second-Generation Antipsychotics: A National Survey of Child Psychiatrists

McLaren

Brunette

McHugo

et al. 2017

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 96%

Monitoring of Patients on Second-Generation Antipsychotics: A National Survey of Child Psychiatrists

McLaren

Brunette

McHugo

et al. 2017

View full text Add to dashboard Cite

show abstract

“…A few, small-sample survey studies have been conducted with Canadian and Australian psychiatrists. These studies document a high level of awareness of potential metabolic and cardiac side effects associated the SGAs, but a limited use of monitoring practices (Doey et al 2007;Walter et al 2008;Morrato et al 2009). Little is known about SGA monitoring beliefs and patterns of United States-based child and adolescent psychiatrists, although recent research has shown that practice setting and physician attitudes influence off-label SGA use in children .…”

Section: Introductionmentioning

confidence: 99%

Child and Adolescent Psychiatrists' Reported Monitoring Behaviors for Second-Generation Antipsychotics

Rodday

Parsons²,

Mankiw³

et al. 2015

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

Objective: The number of children and adolescents (hereafter referred to as ''children'') who have been prescribed secondgeneration antipsychotics (SGAs) has increased over the last decade, but little is known about monitoring practices in pediatric patients who are vulnerable to adverse effects. We examined factors associated with psychiatrists' self-reported monitoring of children who were prescribed SGAs. Methods: A survey was mailed to a national, randomly selected sample of 1600 child and adolescent psychiatrists from the American Medical Association mailing list. Using logistic regression, we tested whether psychiatrist characteristics, attitudes, and practice characteristics were associated with monitoring (baseline and/or periodic) the following: Patient history, height and weight, blood pressure, waist circumference, lipid and glucose levels, and electrocardiogram. Results: Among the analytic sample of 308, at least two thirds reported monitoring patient history, height and weight, blood pressure, and fasting plasma lipids and glucose; 23% reported monitoring waist circumference; and 12% reported conducting an electrocardiogram. More than one third stated that they routinely monitored thyroid levels and more than half reported monitoring complete blood count and electrolytes/blood urea nitrogen. Psychiatrists reporting that they were able to measure vital signs on site were more likely to measure height and weight. Those who reported feeling comfortable conducting a physical examination were more likely to measure blood pressure. Those answering that the risk of metabolic syndrome was low were less likely to measure blood pressure and waist circumference. Being board certified and able to measure vital signs on site were associated with more monitoring of glucose and lipid levels. Conversely, years in practice and feeling that patients were nonadherent with blood work were associated with less monitoring of glucose and lipid levels. Conclusions: In this sample, inconsistent monitoring patterns of children prescribed SGAs were found. Efforts to communicate guidelines' evidence base and improve office capacity to measure and track adverse effects are needed to increase appropriate adverse effect monitoring in children who have been prescribed SGAs.

show abstract

“…Risperidone is the most commonly prescribed antipsychotic drug in paediatric patients [4,12,13]. It has been repeatedly reported that risperidone is associated with much higher weight gain in children and adolescents than those in adults [14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

Risperidone-induced weight gain and reduced locomotor activity in juvenile female rats: The role of histaminergic and NPY pathways

Lian

Santis

et al. 2015

Pharmacological Research

View full text Add to dashboard Cite

. (2015). Risperidone-induced weight gain and reduced locomotor activity in juvenile female rats: the role of histaminergic and NPY pathways. Pharmacological Research,[95][96] Risperidone-induced weight gain and reduced locomotor activity in juvenile female rats: the role of histaminergic and NPY pathways AbstractSecond generation antipsychotic drugs (SGAs) such as risperidone are increasingly prescribed (mostly for offlabel use) to children and adolescents for treating various mental disorders. SGAs cause serious weight gain/ obesity and other metabolic side-effects. This study aimed to establish an animal model of risperidoneinduced weight gain in female juvenile rats, and to investigate the effects of risperidone on the expression of hypothalamic histaminergic H1 receptors (H1R) and neuropeptides, and their association with weight gain. Female Sprague Dawley rats were treated orally with risperidone (0.3 mg/kg, 3 times/day) or vehicle (control) starting from postnatal day (PD) 23 (±1 day) for 3 weeks (a period corresponding to the childhoodadolescent period in humans). In the female juvenile rats, risperidone treatment increased food intake and body weight gain, which started to appear after 12 days' treatment. Risperidone also significantly decreased the locomotor activity of the female rats. Consistently, risperidone significantly elevated mRNA expression of hypothalamic H1R, neuropeptide Y (NPY), and agouti-related peptide (AgRP) compared to controls, and H1R and NPY levels were correlated with risperidone enhanced weight gain and food intake in the female juvenile rats. However, risperidone did not affect hypothalamic proopiomelanocortin (POMC) and cocaineand amphetamine-regulated transcript (CART) mRNA expression. Therefore, these results suggested that risperidone elevated appetite and body weight gain in juveniles via regulation of the hypothalamic H1R, NPY and AgRP pathways, as well as by reducing activity.

show abstract

Side Effects of Second-Generation Antipsychotics: The Experiences, Views and Monitoring Practices of Australian Child Psychiatrists

Cited by 38 publications

References 66 publications

Monitoring of Patients on Second-Generation Antipsychotics: A National Survey of Child Psychiatrists

Monitoring of Patients on Second-Generation Antipsychotics: A National Survey of Child Psychiatrists

Child and Adolescent Psychiatrists' Reported Monitoring Behaviors for Second-Generation Antipsychotics

Risperidone-induced weight gain and reduced locomotor activity in juvenile female rats: The role of histaminergic and NPY pathways

Contact Info

Product

Resources

About